Positive Surgical Margins Linked to Worse RCC Recurrence, Survival Rates
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Survival Improving in Metastatic Bladder Cancer
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
The Cost of Bladder Cancer Care Is Rising. Could Value-Based Care Models Help?
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Fat Loss Portends Worse Prognosis in ICI-Treated Metastatic Clear Cell RCC
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
Radical Cystectomy Increases Risks for Thromboembolic Events
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Partial Cytoreductive Nephrectomy Still Offers Survival Edge in Metastatic RCC
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Cost of Radical Cystectomy Higher in the West Than in Other US Regions
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Benefits Persist for Lenvatinib Plus Pembrolizumab in Renal Cell Cancer
Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.
RCC Stratification System May Need to Be Refined, Data Suggest
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Aortic Calcification Ups Risk for Acute Kidney Injury After Radical Cystectomy
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
Certain Antibiotics May Reduce the Efficacy of Certain ICIs in Cancer Patients
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Identifying and Managing Adverse Reactions to Lenvatinib and Pembrolizumab
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Gemcitabine-Docetaxel Deemed Reasonable Alternative to BCG During Shortage
Gemcitabine plus docetaxel “may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage,” according to researchers.
Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Opioid Prescription Can Be Eliminated After Urologic Cancer Surgery
A protocol for eliminating routine opioid prescription after major urologic cancer surgery was both safe and successful, according to researchers.
Imaging With 89Zr-DFO-Girentuximab Identifies Clear Cell Renal Cell Carcinoma
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Cabozantinib Shows Activity in Advanced RCC After CPI-Based Combinations
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
Pembrolizumab Could Meet Unmet Need in BCG-Unresponsive High-Risk NMIBC
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Metastatic Urothelial Carcinoma
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
High Pretreatment NLR Signals Worse Outcomes in Muscle-Invasive Bladder Cancer
A high pretreatment neutrophil-to-lymphocyte ratio is associated with worse outcomes in patients with muscle-invasive bladder cancer, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...